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Abstract
Introduction: There is a great need for quick tests that identify treatment response in Alzheimer’s disease (AD) to
determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compared
with the mini-mental state examination (MMSE) in the evaluation of treatment outcome in AD.
Methods: 75 patients with mild to moderate AD at a memory clinic were assessed with AQT and the MMSE at a
pretreatment visit, at baseline and after 8 weeks of treatment with cholinesterase inhibitors (ChEI) initiated at
baseline. Changes in the mean test scores before and after treatment were compared, as well as the number of
treatment responders detected by each test, according to a reliable change index (RCI).
Results: After 8 weeks of treatment, the AQT improvement, expressed as a percentage, was significantly greater
than that of the MMSE (P = 0.026). According to the RCI, the cut-offs to define a responder were ≥16 seconds
improvement on AQT and ≥3 points on the MMSE after 8 weeks. With these cut-offs, both tests falsely classified
≤5% as responders during the pretreatment period. After 8 weeks of treatment, AQT detected significantly more
responders than the MMSE (34% compared with 17%; P = 0.024). After 6 months of treatment, the 8-week AQT
responders still showed a significantly better treatment response than the AQT nonresponders (22.3 seconds in
mean difference; P < 0.001).
Conclusions: AQT detects twice as many treatment responders as the MMSE. It seems that AQT can, already after
8 weeks, identify the AD patients who will continue to benefit from ChEI treatment.
Introduction
An estimated population of more than 29 million people
worldwide suffered from dementia in 2005 at a cost of US
$315 billion [1]. Of all dementia cases, approximately 60%
to 70% have Alzheimer’s disease (AD) [2,3]. The treatment
of AD consists mainly of cholinesterase inhibitors (ChEI),
which improve behavior, activities of daily living, and cog-
nitive functions in AD patients [4]. However, not every
patient benefits from this treatment. To enhance the drug
efficacy and its cost benefits in AD populations, the pub-
lished guidelines on drug therapy emphasize the impor-
tance of identifying those who have responded positively
to the treatment [5-7]. Because of the vast number of
patients with AD, the evaluation will predominantly have
to be conducted in primary care centers, and a simple and
quick evaluation test is therefore desirable. The test should
also be reliable and sensitive to the specific cognitive
changes caused by the treatment.
Ap o s s i b l ec a n d i d a t ef o rt h i sk i n do ft e s ti sAQ u i c k
Test of cognitive speed (AQT), which is a well-validated,
sensitive screening tool for cognitive impairment and AD
[8] (Figure 1). The AQT takes 3 to 5 minutes to adminis-
ter, has no ceiling or floor effect, and is independent of
gender, education, and culture [9,10]. Previous studies
have shown that the AQT activates temporoparietal cor-
tical areas, which are the major brain regions affected in
AD [11]. Moreover, one of the main functions measured
by the AQT is attention [12], which is the cognitive func-
tion that often improves the most from ChEI treatment
in AD [13,14]. This makes the AQT a promising test for
detecting treatment response in AD. The most common
test for evaluating ChEI treatment is the Mini-Mental
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mended cognitive test for the evaluation of treatment
with ChEI, according to the National Institute for Health
and Clinical Excellence (NICE) [5]. This makes MMSE a
suitable reference test to compare with the AQT.
An optimal cognitive evaluation test of treatment
response will, at a given cut-off, classify very few patients
as treatment responders when no treatment is given and
as many as possible when treatment is given. To define
the cut-off for treatment response, one must consider
f a c t o r ss u c ha sc o g n i t i v ef l u c tuation of the patients, low
test reliability, training effect, and so on. These factors
cause changes in test score that are not caused by the
treatment and therefore must be accounted for. The
most common way of doing that is by establishing a reli-
able change index (RCI) [16]. RCI is a statistical analysis
for detecting individually significant change, and it has
been used in more than 500 medical studies.
The aim of this study was to
1. Compare the changes of AQT and the MMSE
before and after ChEI treatment in AD patients.
2. Compare the ability of AQT and the MMSE to
detect treatment responders according to cut-offs calcu-
lated by RCI analyzes.
Materials and methods
Patients
The AD patients were enrolled from a part of the Swed-
ish Alzheimer’s Treatment Study (SATS) located in the
town of Malmö, Sweden [17]. SATS is a prospective,
open-label study in routine clinical settings, which have
collected patients who have been referred to the Memory
Clinic at Malmö University Hospital and have met the
criteria for AD according to NINCDS-ADRDA [18]. In
addition to a clinical examination by physicians specializ-
ing in dementia disorders, the patients were examined
with brain computed tomography, routine blood samples,
and cerebrospinal fluid analysis. After the baseline visit,
treatment with rivastigmine, donepezil, or galantamine
was initiated. The patients were followed up in a struc-
tured program with assessments at baseline, 8 weeks,
6 months, and semiannually thereafter. For patients to be
enrolled from SATS to this study, they had to have
MMSE and AQT color-form (AQT-CF) scores from a
visit at a predefined time period of 1 to 6 months before
baseline, the baseline visit, and the visit at 8 weeks after
baseline. The MMSE and AQT scores had to be from the
same occasions. Only patients with an MMSE score of
13 points or more and an AQT-CF score of 190 seconds
or less at baseline were included because test changes are
difficult to assess in patients with very poor test perfor-
mance, because of low reliability [19]. The cut-offs were
predefined and not based on the current study popula-
tion, which otherwise could introduce selection bias. The
inclusion criteria generated a study population of 75 AD
patients. They had been followed at the clinic over a
mean ± standard deviation (SD) period of 32 ± 19
months and had been reviewed by the study doctors S.P.
and O.H. from a longitudinal perspective in regard to
diagnosis accuracy. All patients lived at home and had a
mean age of 77 ± 6.7 years. Seventy-one percent were
women. Sixty-five percent were treated with galantamine,
18% with rivastigmine, and 17% with donepezil. The
mean doses of the drugs during the 8 weeks of treatment
were 9.9 mg, 3.7 mg, and 5.4 mg, respectively.
A written informed consent was obtained from all
patients and proxies. The study was approved by the
ethics committee of Lund University, Sweden, and was
carried out in accordance with the Helsinki Declaration.
MMSE and AQT
Specialized dementia nurses administered both tests
according to standardized guidelines to maximize
interrater reliability. The attention part of the MMSE
Figure 1 A sample of AQT. Each original test plate contains 40 figures. The patient is instructed to quickly name the color of each figure on the
first test plate (AQT-C), the form on the second plate (AQT-F), and the color and form on the third plate (AQT-CF) [8]. Only AQT-CF results were
analyzed in this study.
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The backward spelling was used if the patient could
not perform simple arithmetic exercises [21].
AQT measures attention and cognitive speed, has
shown high test-retest reliability (r = 0.91 to 0.95), and
exhibits no habituation or learning in repeated trials
over 10 minutes [22]. AQT-CF has been validated
against WAIS-III P IQ (r = -0.61; P <0 . 0 1 ) ,M M S E( r =
-0.72; P < 0.01) and ADAS-cog (r = 0.63; P <0 . 0 1 ;c o r -
relation made after 6 months of ChEI treatment in AD)
[12,23]. It has shown no significant correlation with the
Trail Making Test (TMT), verbal association fluency
(FAS), or Rey Complex Figure Test (RCFT) [12]. The
test scores constitute the number of seconds it takes for
a patient to complete each test plate (Figure 1). The test
was performed in Swedish, which has produced the
same results as a test performed in English [10]. Only
A Q T - C Fw a sa n a l y z e di nt h i ss t u d yb e c a u s ei ti st h e
most validated and sensitive part of AQT and contains
the cognitive measures that are mostly associated with
AD [22].
Assessing test changes: Reliable Change Index
RCI provides a confidence interval (CI), which repre-
sents the predicted changes that would occur if a
patient’s test score does not change significantly from
one assessment to another. The most commonly used
CI is 90% [24-27], which was also used in this study.
With this CI, about 5% in a stable control group will
show a test improvement (according to a cut-off value
b a s e do nt h eR C I ) ,e v e nw h e nn oi n t e r v e n t i o no rr e a l
change has occurred. The RCI is calculated from a con-
trol group by considering the test-retest reliability, SD,
and a systematic bias of the score change between the
first and second test occasion (for example, training
effect or disease progression) [24]. The formulae that
describe this can be found in Additional file 1. Instead
of calculating the RCI based on changes in a healthy
control group, the RCI was calculated from the changes
of the AD patients during the untreated period. The
MMSE and AQT changes from before baseline to base-
line were thus used to calculate an interval of “normal”
test changes when no treatment was given (that is, the
RCI). Test changes during the treatment period greater
than the RCI were considered to be due to treatment
effect. By using the same population as controls (the
period from before baseline to baseline) and as cases
(the period from baseline to postbaseline), one elimi-
nates many confounding factors such as test-score varia-
bility (which is more pronounced in AD than in healthy
controls), age, disease progression, gender, and so on.
Because of the clinical nature of this study, the test
interval before treatment varied from 1 to 6 months,
with a mean ± SD interval of 3.7 ± 1.2 months. Because
of the progressive nature of AD, a longer prebaseline
test interval would likely show a greater deterioration.
Therefore, an approximated score at 8 weeks before
baseline was calculated for each patient. The 8 weeks
prebaseline score was calculated in the following way:
8 × (baseline score - prebaseline score)/Number of
weeks between the prebaseline and baseline visit. These
approximated scores were then used to calculate the
test changes during 8 weeks before treatment (baseline
score - 8 weeks prebaseline score), which provided a
single test-retest interval to be compared with the
changes after 8 weeks of treatment.
For patients with a test interval of 1 to 3 months
before baseline, the mean 8 weeks prebaseline MMSE
score was 22.7 ± 3.3 points, and the mean 8 weeks pre-
baseline AQT-CF score was 97.3 ± 22.8 seconds. Those
with an interval of 4 to 6 months before baseline had a
mean 8 weeks prebaseline MMSE score of 23.1 ± 3.1
points and a mean prebaseline AQT-CF score of 99.4 ±
21.4 seconds. No significant differences were found
between the groups regarding the calculated 8 weeks
prebaseline MMSE and AQT scores (P >0 . 5 0 ) .C o n s e -
quently, the fact that AQT and the MMSE were admi-
nistered at different intervals before treatment did not
seem to have any impact on the calculated 8 weeks pre-
baseline scores. Previous RCI studies have also used a
varied interval between test occasions, but without cor-
recting for this (calculating a single test-retest interval)
or testing the homogeneity of the group [24,26,27]. We
believe our method provides a more valid RCI result
because the calculations are based on the same interval
(8 weeks without treatment) to which it is going to be
applied (8 weeks with treatment).
Statistical analysis
The RCI was calculated as described in previous studies
(see Additional file 1) [27]. Variables that followed a
normal distribution were analyzed with parametric
statistics, and significantly skewed variables, with non-
parametric statistics. The MMSE and AQT changes
were assessed with the Wilcoxon matched-pairs signed
ranks test. The test changes expressed as percentages
were analyzed with the paired t test. The McNemar test
was used when comparing the number of MMSE and
AQT responders. Linear relations were examined by
using Pearson correlation. The statistical analyses were
performed by using Statistical Package for Social
Sciences (SPSS) software (version 17.0; SPSS Inc.,
Chicago, IL).
Results
Changes in test scores
The MMSE and AQT scores are shown in Table 1. It is
important to note that a negative AQT change and a
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the 8-week pre-baseline period when the patients had
not yet received any treatment, mean AQT deteriorated
significantly by 2.6 seconds (P < 0.05), whereas the
mean MMSE deteriorated nonsignificantly by -0.29
points (P = 0.09). After 8 weeks of treatment, the mean
AQT score improved by -9.7 seconds compared with
baseline (P < 0.0001), and the mean MMSE score
improved 0.6 points (P < 0.05; Table 1).
To compare the test changes of MMSE and AQT in a
statistical manner, the score changes of each patient
must be expressed as a percentage of the previous score
because the tests consist of different scales (Figure 2).
When just comparing the AQT and MMSE changes after
treatment, AQT indicated a somewhat more pronounced
improvement than did the MMSE (P = 0.06). However, it
is important to account for the individual disease-pro-
gression rate (score change before treatment) because
this affects the degree of change in test scores after treat-
ment. The individual test changes of AQT and MMSE
during the 8 weeks before treatment were thus sub-
tracted from the changes after 8 weeks of treatment. This
meant that if a patient deteriorated 5% in a test score
before treatment and improved 10% after treatment, the
total treatment effect was an improvement of 15%
(assuming that the patient would continue to deteriorate
5% during the 8 weeks after baseline if no treatment had
been given). After correcting for individual disease pro-
gression, AQT improved by 10.8%, and the MMSE
improved by 3.7% (Figure 2) When analyzing these
values, the improvement of AQT was significantly greater
than that of the MMSE (95% CI of the difference: 0.9% to
13.3%; P = 0.026).
Treatment responders according to the Reliable Change
Index
The Reliable Change Index (RCI) results are summarized
in Figure 3. The test-retest reliability (Pearson correla-
tion) used in the RCI formula was based on the baseline
and 8-week pre-baseline occasions. The correlation coef-
f i c i e n to fA Q Tw a s0 . 8 7( P < 0.001), and for the MMSE,
0.86 (P < 0.001). The 90% CI to state if a significant
change had occurred on an individual basis (the RCI) was
-15.5 to +20.5 seconds for AQT. That is, if a patient
improved more than -15.5 seconds, a significant
improvement had occurred (clinically this meant that
everyone with a -16-second improvement, because only
whole seconds were measured). Patients who improved
Table 1 Mean MMSE and AQT values ± standard deviation
Variable 8 weeks before baseline
e Baseline 8 weeks after baseline
n =7 5 n =7 5 n =7 5
The MMSE, points 23.0 ± 3.1 22.7 ± 3.0
a 23.3 ± 3.5
b*
AQT Color-Form, seconds 98.8 ± 21.6 101.5 ± 24.9
c* 91.8 ± 28.4
d*
aP = 0.088 compared with 8 weeks before baseline.
bP = 0.047 compared with baseline.
cP = 0.045 compared with 8 weeks before baseline.
dP < 0.0001
compared with baseline.
eCalculated value for all 75 patients according the description in Materials and methods. *Significant change.
Calculated with the Wilcoxon test. MMSE, the Mini-Mental State Examination (0 to 30 points); a higher score indicates better cognition. AQT, A Quick Test of
cognitive speed (measured in seconds); less time indicates better cognition.
Figure 2 Mean values of the score changes expressed as percentages. The lines show the changes from 8 weeks before baseline to
baseline and from baseline to 8 weeks after baseline. Dashed lines represent assumed deterioration without treatment. Error bars represent
standard error of the mean.
1 Comparison of the AQT and MMSE improvements after treatment when accounting for disease progression
(calculated with paired samples t test).
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the RCI was -2.99 to +2.41 points (that is, those with at
least a +3-point improvement were responders). After
8 weeks of treatment, AQT detected 26 treatment
responders (34%), whereas the MMSE detected 13 (17%)
treatment responders (Figure 3). As expected according
to the RCI, both test cut-offs falsely classified ≤5%
responders during the pretreatment period (Figure 3). A
“false responder” in this case is a patient who improved
more than the RCI during the period when no treatment
was given. After treatment, ≤5% of all the patients dete-
riorated more than the RCI of AQT and the MMSE,
which also is just as expected.
Unsurprisingly, the AQT-treatment responders
showed greater improvement after 8 weeks of treatment
compared with the nonresponders in mean AQT score
(P < 0.0001). However, a major significant difference in
mean AQT change between the groups was still found
Figure 3 Responders. Percentage responders after 8 weeks without treatment and after 8 weeks with treatment according to cut-offs derived
from RCI. Details on the RCI analysis can be found in Additional file 1. Calculated with the McNemar test.
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classified as treatment responders by AQT after 8 weeks
of treatment showed a mean improvement of -19.3 ±
22.3 seconds on AQT after 6 months of treatment. The
nonresponders, conversely, deteriorated 3.3 ± 13.5 sec-
onds over the 6-month treatment period. Thus, the
AQT responders at the 8-week visit continued clearly to
show a better treatment response at the 6-month visit
compared with the nonresponders (P < 0.0001).
Discussion
In this study, we evaluated AQT as a test for detecting
early ChEI treatment response in AD and compared it
with the MMSE. After 8 weeks of treatment, AQT had
improved significantlym o r et h a nt h eM M S Ew h e n
accounting for disease progression (Figure 2). Further,
AQT identified twice as many treatment responders as did
the MMSE (34% compared with 17%; p = 0.02; Figure 3).
The increased number of responders cannot be explained
by low reliability or random changes of AQT scores,
because AQT classified only 5% (false) responders during
the 8-week period before treatment (Figure 3). Finally,
when comparing the AQT responders and nonresponders
from the 8-week visit, the responders still showed a signifi-
cantly better treatment response after 6 months of treat-
ment. This indicates that AQT detects early treatment
responders who seem to continue to benefit from ChEI
treatment.
Evaluation of treatment
Good clinical practice and cost-benefit considerations
require that all AD patients be evaluated before and after
the initiation of treatment to determine whether the
treatment shall continue [5]. The most common test for
this evaluation in clinical practice is the MMSE, and this
is also the recommended test according to the NICE
guidelines [5]. In clinical trials, the ADAS-cog is the most
commonly used cognitive test [28,29]. It measures a
broader span of cognitive functions, but has the disad-
vantage of taking 45 minutes to administer compared
with 3 to 5 minutes for AQT and 10 to 15 minutes for
the MMSE. Because of the length of the ADAS-cog, it
cannot really be regarded as a brief cognitive test suitable
for clinical practice. ADAS-cog and the MMSE are well
studied for ChEI evaluation of AD, but no previous
studies of AQT were performed in this context. However,
in a recent randomized, placebo-controlled, multinational
study, AQT was used to evaluate the treatment effect of
memantine on dementia with Lewy bodies and Parkinson
disease dementia [30]. In that study, both AQT and the
global cognitive measure CGIC improved significantly
after 24 weeks of treatment, compared with placebo,
whereas the MMSE failed to improve significantly.
Future evaluation issues
In the future, it is likely that more patients with mild
cognitive impairment (MCI) will be included in thera-
peutic trials and treated in clinical practice. It is then
essential to have a sensitive test with no ceiling effect.
The MMSE and the ADAS-cog have detected in MCI
studies significant cognitive changes [31,32], but they
have also been criticized for their ceiling effects and
inability to detect small cognitive changes [28]. In the
only study in which AQT has been used to evaluate
MCI treatment, AQT improved significantly, whereas
the other cognitive tests failed to do so (WAIS III Digit
Span, WAIS-R NI Spatial Span, Digit Symbol Modalities,
and Rey’s Complex Figure Test) [33]. Further, AQT has
no ceiling effect and, in this study, was able to signifi-
cantly detect the subtle disease progress of AD during
the nontreatment period of 8 weeks (Table 1). Although
the results are promising, more studies are needed to
warrant the sensitivity of AQT to cognitive change and
to systematically compare it with the MMSE and the
ADAS-cog.
Another important future issue is that by 2040, it is
predicted that 71% of all dementia patients will be in
developing countries [34]. Therefore, the International
Psychogeriatric Association (IPA) and the Alzheimer’s
Association have pointed out the need for a culturally
independent test [7,28]. AQT has so far been validated
in Western, Arabic, and African countries and does not
exhibit any culturally dependent questions or exercises
[8,9,35], whereas the MMSE is affected by ethnicity
[36,37].
Detecting treatment responders
In the present study, we evaluated the treatment response
after 8 weeks. Previously, it was shown that 4 to 8 weeks
of AD treatment results in a significant treatment effect
compared with placebo [38-41]. This supports our evalua-
tion of treatment effects already after 8 weeks. It is also is
in agreement with the guidelines by NICE and the Ameri-
can College of Physicians (ACP) [5,7]. When evaluating
the treatment response, the ACP has suggested that a 3-
point change in the MMSE indicates a clinically significant
change [7]. This is also the same result as the present
s t u d yf o u n dt oi n d i c a t eas i g n i f i c a n tc h a n g e( F i g u r e3 ) .
Unfortunately, no comparable studies are available regard-
ing individual change on AQT.
This study used a statistical method (RCI) to deter-
mine treatment responders according to the MMSE and
AQT. The clinical relevance of an MMSE improvement
of at least 3 points or an AQT improvement of at least
16 seconds is uncertain. In the entire population, the
clinical relevance of a mean AQT improvement of
10.8% and a mean MMSE improvement of 3.7% is also
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only used to compare the MMSE and AQT as evalua-
tion instruments. To determine a clinically meaningful
AQT or MMSE change, a minimal clinically important
difference (MCID) must be defined. One approach to
determine the MCID for AD could be to measure the
natural history of decline over 12 months or longer in a
large group of patients by using AQT, the MMSE, and a
global rating of the cognitive performance. A definition
of MCID could then be the percentage of change on the
MMSE or AQT that is anchored against the natural his-
tory of global change in AD.
According to the cut-off values, AQT detected signifi-
cantly more responders after 8 weeks of treatment than
did the MMSE (34% compared with 17%; P = 0.026),
while falsely detecting 5% responders when no treat-
ment was given (Figure 3). This indicates that AQT is a
more-sensitive evaluation tool, which is further empha-
sized by the changes on a group level. AQT improved
s i g n i f i c a n t l ym o r ea f t e rtreatment than did the MMSE
when accounting for disease progression (Figure 2). The
more-pronounced sensitivity of AQT compared with the
MMSE might be explained by their different scales and
the different cognitive functions that are measured. Stu-
dies have shown that ChEI mostly improves attention
[13,14], which is one of the main cognitive domains
measured by AQT. It is possible that the treatment
response in our study could have been higher if all ChEI
doses had been increased after 4 weeks of treatment
(the dose was often increased after 8 weeks). This
should, however, not affect the comparison between
AQT and the MMSE.
Intuitively, it seems that patients who exhibit the right
characteristics initially to have a positive treatment
response would continue to benefit from the medica-
tion. This assumption has been debated, and to deter-
mine whether it is true, the reliability and validity of the
evaluation instrument must be high. In our study, we
found that the AD patients who were classified as treat-
ment responders by AQT after 8 weeks of treatment
still performed significantly better on AQT after 6
months, compared with the patients classified as nonre-
sponders after 8 weeks (22.6 seconds in mean difference;
P < 0.0001). This indicates that AQT might be used
after 8 weeks of ChEI treatment to identify those who
will continue to benefit from the treatment.
Two advantages of this study are that the treatment
was evaluated prospectively and that the same population
w a su s e db o t ha sc o n t r o l sa n da sc a s e s .T h el a t t e ri st h e
most important factor for reliable RCI results, as most
confounding factors are eliminated. A shortcoming was
that this was not a randomized study with a placebo
group, but instead a study with a control group. The
treatment effect can therefore not with certainty be sepa-
rated from the placebo effect. However, placebo treat-
ment in clinical trials of AD patients has not resulted in
significant improvements of any cognitive tests [38-41].
Furthermore, the lack of a placebo group should not
affect the comparison of the MMSE and AQT.
Conclusions
In conclusion, AQT, a quick test of cognitive speed and
attention, seems to be twice as sensitive as the MMSE
in detecting early treatment response to ChEI in AD
patients. The early responders detected by AQT contin-
ued to benefit from ChEI after 6 months of treatment.
This indicates the potential usefulness of AQT when
evaluating treatment effects in clinical routine, especially
in primary care units. Moreover AQT may be important
when evaluating new treatments in the early stages of
AD, because of its sensitivity and lack of ceiling effect.
Further studies are needed to compare the treatment
response detected by AQT and brief cognitive tests
other than the MMSE.
Additional material
Additional file 1: Reliable Change Index (RCI). Statistical information
on how the RCI was calculated.
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